文献速递临床试验与 GCP流行病学与生物统计

裸盖菇素、麦角酸二乙酰胺、3,4-亚甲二氧基甲基苯丙胺、死藤水与艾司西酞普兰口服单药治疗抑郁症状的比较:系统综述与贝叶斯网状Meta分析

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
PubMed 文献 · BMJ · 2024-08-21

该系统综述与贝叶斯网状Meta分析纳入截至2023年10月12日的随机对照试验,评估口服裸盖菇素、麦角酸二乙酰胺、3,4-亚甲二氧基甲基苯丙胺、死藤水与艾司西酞普兰单药治疗抑郁症状的效果与可接受性。主要结局为17项汉密尔顿抑郁量表评分变化。在抗抑郁药试验中,仅高剂量裸盖菇素优于安慰剂(均差6.45,95%可信区间3.19至9.41),但效应量由大(0.88)降至小(0.31)。

要点

  • 致幻剂试验中安慰剂反应低于艾司西酞普兰抗抑郁药试验(均差-3.90,95%可信区间-7.10至-0.96)。
  • 在艾司西酞普兰抗抑郁药试验中,仅高剂量裸盖菇素优于安慰剂,均差6.45(95%可信区间3.19至9.41)。
  • 高剂量裸盖菇素效应量随参照组变化由大(0.88)降至小(0.31)。

核心结论

  • 在现有致幻剂治疗抑郁症状的研究中,高剂量裸盖菇素在抗抑郁药试验中显示出优于安慰剂的反应,但效应量小。

研究设计与样本

  • 系统综述与贝叶斯网状Meta分析,检索Medline、Cochrane对照试验中心注册库、Embase、PsycINFO、ClinicalTrial.gov及世界卫生组织国际临床试验注册平台,从建库至2023年10月12日。
  • 纳入成年抑郁症状患者的致幻剂或艾司西酞普兰随机对照试验;致幻剂试验要求口服单药治疗且不联用抗抑郁药。
  • 主要结局为17项汉密尔顿抑郁量表评分变化;次要结局为全因停药和严重不良事件。
  • 采用贝叶斯框架下的随机效应模型合并数据,并区分致幻剂试验与抗抑郁药试验的安慰剂反应以避免估计偏倚。

主要发现

  • 致幻剂试验中安慰剂反应低于艾司西酞普兰抗抑郁药试验,均差-3.90(95%可信区间-7.10至-0.96)。
  • 在致幻剂试验中多数致幻剂优于安慰剂,但在艾司西酞普兰抗抑郁药试验中仅高剂量裸盖菇素优于安慰剂,均差6.45(95%可信区间3.19至9.41)。
  • 高剂量裸盖菇素的效应量(标准化均差)在参照臂从致幻剂试验的安慰剂反应改为抗抑郁药试验后,由大(0.88)降至小(0.31)。
  • 高剂量裸盖菇素的相对效应大于艾司西酞普兰10 mg(4.66,95%可信区间1.36至7.74)和20 mg(4.69,95%可信区间1.64至7.54)。
  • 无干预措施与安慰剂相比在全因停药或严重不良事件方面相关。

关键数值与推荐

  • 高剂量裸盖菇素 vs 安慰剂(抗抑郁药试验):均差6.45(95%可信区间3.19至9.41)。
  • 致幻剂试验安慰剂反应 vs 艾司西酞普兰抗抑郁药试验安慰剂反应:均差-3.90(95%可信区间-7.10至-0.96)。
  • 高剂量裸盖菇素 vs 艾司西酞普兰10 mg:相对效应4.66(95%可信区间1.36至7.74)。
  • 高剂量裸盖菇素 vs 艾司西酞普兰20 mg:相对效应4.69(95%可信区间1.64至7.54)。
  • 高剂量裸盖菇素效应量(标准化均差):参照致幻剂试验安慰剂时为0.88,参照抗抑郁药试验时为0.31。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms, considering the potential for overestimated effectiveness due to unsuccessful blinding. DESIGN: Systematic review and Bayesian network meta-analysis. DATA SOURCES: Medline, Cochrane Central Register of Controlled Trials, Embase, PsycINFO, ClinicalTrial.gov, and World Health Organization's International Clinical Trials Registry Platform from database inception to 12 October 2023. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials on psychedelics or escitalopram in adults with depressive symptoms. Eligible randomised controlled trials of psychedelics (3,4-methylenedioxymethamphetamine (known as MDMA), lysergic acid diethylamide (known as LSD), psilocybin, or ayahuasca) required oral monotherapy with no concomitant use of antidepressants. DATA EXTRACTION AND SYNTHESIS: The primary outcome was change in depression, measured by the 17-item Hamilton depression rating scale. The secondary outcomes were all cause discontinuation and severe adverse events. Severe adverse events were those resulting in any of a list of negative health outcomes including, death, admission to hospital, significant or persistent incapacity, congenital birth defect or abnormality, and suicide attempt. Data were pooled using a random effects model within a Bayesian framework. To avoid estimation bias, placebo responses were distinguished between psychedelic and antidepressant trials. RESULTS: Placebo response in psychedelic trials was lower than that in antidepression trials of escitalopram (mean difference -3.90 (95% credible interval -7.10 to -0.96)). Although most psychedelics were better than placebo in psychedelic trials, only high dose psilocybin was better than placebo in antidepression trials of escitalopram (mean difference 6.45 (3.19 to 9.41)). However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials. The relative effect of high dose psilocybin was larger than escitalopram at 10 mg (4.66 (95% credible interval 1.36 to 7.74)) and 20 mg (4.69 (1.64 to 7.54)). None of the interventions was associated with higher all cause discontinuation or severe adverse events than the placebo. CONCLUSIONS: Of the available psychedelic treatments for depressive symptoms, patients treated with high dose psilocybin showed better responses than those treated with placebo in the antidepressant trials, but the effect size was small. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023469014.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Hsu TW, Tsai CK, Kao YC, et al. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ. 2024. PMID: 39168500. doi:10.1136/bmj-2023-078607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。